ArticlePloS one2011

Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance.

Eftychia Oikonomou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.